Evidence map›Paper›PMID 30090809›Full record

ArticleFrontiers in medicine2018

A Conceptual Framework for Optimizing Blood Matching Strategies: Balancing Patient Complications Against Total Costs Incurred.

Joost H J van Sambeeck, Puck D de Wit, Jessie Luken, Barbera Veldhuisen, Katja van den Hurk, Anne van Dongen, Maria M W Koopman, Marian G J van Kraaij, C Ellen van der Schoot, Henk Schonewille and 2 more

Abstract read
In one paragraph

Article in Frontiers in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Joost H J van SambeeckDepartment of Transfusion Technology Assessment, Sanquin Research, Amsterdam, Netherlands.
Puck D de WitDepartment of Donor Studies, Sanquin Research, Amsterdam, Netherlands.
Jessie LukenSanquin Diagnostic Services, Amsterdam, Netherlands.
Barbera VeldhuisenSanquin Diagnostic Services, Amsterdam, Netherlands.
Katja van den HurkDepartment of Donor Studies, Sanquin Research, Amsterdam, Netherlands.
Anne van DongenDepartment of Donor Studies, Sanquin Research, Amsterdam, Netherlands.
Maria M W KoopmanDepartment of Transfusion Medicine, Sanquin Blood Bank, Amsterdam, Netherlands.
Marian G J van KraaijDepartment of Transfusion Medicine, Sanquin Blood Bank, Amsterdam, Netherlands.
C Ellen van der SchootSanquin Research and Landsteiner Laboratory, Department of Experimental Immunohematology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Henk SchonewilleSanquin Research and Landsteiner Laboratory, Department of Experimental Immunohematology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Wim L A M de KortDepartment of Donor Studies, Sanquin Research, Amsterdam, Netherlands.
Mart P JanssenDepartment of Transfusion Technology Assessment, Sanquin Research, Amsterdam, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alloimmunization is currently the most frequent adverse blood transfusion event. Whilst completely matched donor blood would nullify the alloimmunization risk, this is practically infeasible. Current matching strategies therefore aim at matching a limited number of blood groups only, and have evolved over time by systematically including matching strategies for those blood groups for which (serious) alloimmunization complications most frequently occurred. An optimal matching strategy for controlling the risk of alloimmunization however, would balance alloimmunization complications and costs within the entire blood supply chain, whilst fulfilling all practical requirements and limitations. In this article the outline of an integrated blood management model is described and various potential challenges and prospects foreseen with the development of such a model are discussed.

Indexed as

alloimmunizationblood supply chaincost-effectivenessmodelingoptimization

Identifiers

PMID30090809
PMCPMC6069448

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.